AVEO Pharmaceuticals Inc.

7.79-0.2100-2.62%Vol 154.85K1Y Perf 38.65%
Aug 11th, 2022 16:00 DELAYED
BID7.60 ASK8.20
Open8.05 Previous Close8.00
Pre-Market- After-Market-
 - -  - -%
Target Price
16.00 
Analyst Rating
Strong Buy 1.00
Potential %
105.39 
Finscreener Ranking
★★★     49.23
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★+     42.09
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★     44.50
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
92.02 
Earnings Rating
Strong Sell
Market Cap269.64M 
Earnings Date
4th Aug 2022
Alpha0.00 Standard Deviation0.25
Beta0.79 

Today's Price Range

7.638.05

52W Range

3.068.20

5 Year PE Ratio Range

-20.30-6.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.13%
1 Month
10.97%
3 Months
118.21%
6 Months
118.21%
1 Year
38.65%
3 Years
19.81%
5 Years
-73.23%
10 Years
-91.00%

TickerPriceChg.Chg.%
AVEO7.79-0.2100-2.62
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
88.50
-60.00
-59.90
-311.00
-54.04
RevenueValueIndustryS&P 500US Markets
53.74M
1.56
56.47
47.71
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.27-0.2411.11
Q01 2022-0.26-0.30-15.38
Q04 2021-0.35-0.2140.00
Q03 2021-0.36-0.3016.67
Q02 2021-0.47-0.48-2.13
Q01 2021-0.55-0.72-30.91
Q04 2020-0.38-0.44-15.79
Q03 2020-0.24-0.33-37.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.28-21.74Negative
9/2022 QR-0.30-36.36Negative
12/2022 FY-1.06-19.10Negative
12/2023 FY-0.0325.00Positive
Next Report Date-
Estimated EPS Next Report-0.27
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume154.85K
Shares Outstanding34.61K
Shares Float30.42M
Trades Count1.72K
Dollar Volume1.21M
Avg. Volume293.37K
Avg. Weekly Volume418.02K
Avg. Monthly Volume228.60K
Avg. Quarterly Volume233.50K

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) stock closed at 7.79 per share at the end of the most recent trading day (a -2.62% change compared to the prior day closing price) with a volume of 154.85K shares and market capitalization of 269.64M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. AVEO Pharmaceuticals Inc. CEO is Michael P. Bailey.

The one-year performance of AVEO Pharmaceuticals Inc. stock is 38.65%, while year-to-date (YTD) performance is 66.1%. AVEO stock has a five-year performance of -73.23%. Its 52-week range is between 3.06 and 8.2, which gives AVEO stock a 52-week price range ratio of 92.02%

AVEO Pharmaceuticals Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 6.47, a price-to-sale (PS) ratio of 4.28, a price to cashflow ratio of 19.50, a PEG ratio of 2.32, a ROA of -37.90%, a ROC of -40.75% and a ROE of -78.63%. The company’s profit margin is -54.04%, its EBITDA margin is -59.90%, and its revenue ttm is $53.74 Million , which makes it $1.56 revenue per share.

Of the last four earnings reports from AVEO Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. AVEO Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for AVEO Pharmaceuticals Inc. is Strong Buy (1), with a target price of $16, which is +105.39% compared to the current price. The earnings rating for AVEO Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AVEO Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AVEO Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.17, ATR14 : 0.46, CCI20 : 154.05, Chaikin Money Flow : 0.05, MACD : 0.44, Money Flow Index : 59.61, ROC : 16.62, RSI : 62.05, STOCH (14,3) : 86.44, STOCH RSI : 0.74, UO : 57.20, Williams %R : -13.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AVEO Pharmaceuticals Inc. in the last 12-months were: Michael P. Bailey (Buy at a value of $97 200)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.

CEO: Michael P. Bailey

Telephone: +1 617 588-1960

Address: One Broadway, Cambridge 02142, MA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

69%31%

Bearish Bullish

66%34%

TipRanks News for AVEO

Tue, 09 Aug 2022 02:10 GMT Analysts Offer Insights on Healthcare Companies: AVEO Pharma (AVEO), Neurocrine (NBIX) and Tandem Diabetes Care (TNDM)

- TipRanks. All rights reserved.

Fri, 05 Aug 2022 12:45 GMT Analysts Offer Insights on Healthcare Companies: AVEO Pharma (AVEO), Vertex Pharmaceuticals (VRTX) and Bausch + Lomb Corporation (BLCO)

- TipRanks. All rights reserved.

Thu, 19 May 2022 03:45 GMT Analysts Top Healthcare Picks: AVEO Pharma (AVEO), MannKind (MNKD)

- TipRanks. All rights reserved.

Sun, 08 May 2022 15:16 GMT AVEO Pharma (AVEO) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Wed, 16 Mar 2022 02:05 GMT AVEO Pharma (AVEO) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits